Morgan Stanley reiterated coverage on Karyopharm Therapeutics with a new price target

10/12/21 8:28:27 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Morgan Stanley reiterated coverage of Karyopharm Therapeutics with a rating of Overweight and set a new price target of $27.00 from $29.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$KPTI

Date	Price Target	Rating	Analyst
1/19/2023	$8.00	Overweight	Piper Sandler
11/4/2022	$7.00 → $10.00	Sector Perform → Outperform	RBC Capital Mkts
3/8/2022	$12.00 → $8.00	Sector Perform	RBC Capital
3/2/2022	$8.00 → $6.00	Market Perform	SVB Leerink
2/9/2022	$8.00	Underweight → Neutral	JP Morgan
1/10/2022	$6.00 → $8.00	Market Perform	SVB Leerink
12/9/2021	$8.00 → $9.00	Sector Perform	RBC Capital
11/19/2021	$27.00 → $10.00	Overweight → Equal-Weight	Morgan Stanley